Alkermes plc

NASDAQ:ALKS

Biotechnology

Healthcare
$46.85 +1.77%

+$0.79 today

Market cap
$7.87B
Beta
0.33
P/E (TTM)
49.1
EPS (TTM)
$0.92
52W Low $25.17High $45.76

Volume 1.39M

Average 2.33M

ALKS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Alkermes plcNASDAQ: ALKS

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development grows in line with its trailing trend

Q3 FY2026 research & development of $121.12M rose 48.2% year over year, behind the +49.7% change in trailing-twelve-month research & development. Sequentially, it rose 7.3% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.

Context

  • Research & development amounted to 22.0% of revenue in FY2025, up 6.2 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +48.2% toward the trailing-twelve-month pace of +49.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$121.12M+7.3% QoQ
Last fiscal yearDec 2025
$323.96M+32.1% YoY
LTMSep 2026
$430.42M+49.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.2%——
1 year+32.1%——
3-year CAGR+5.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
323.96M USD
Year-over-year change
+32.1%
4-year CAGR
+2.7%

Research & Development vs competitors

How ALKS compares with its peers on the latest reported figures

  • ALKS's LTM Sep 2026 research & development of $430.42M is the 3rd highest of the 7 companies compared; the peer median is $253.66M.
  • Its year-over-year change of +49.7% is the highest of 7, against a peer median of +5.5%.
  • Research & development amounts to 24.5% of revenue for ALKS, versus a peer median of 25.4%.
ALKS Competitors Peer median
Research & Development for ALKS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.23B +30.7%+29.9%33.3%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$623.61M -26.8%+9.9%13.2%
ALKSAlkermes plcLTM Sep 2026$430.42M +49.7%+5.9%24.5%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$319.46M -7.3%-3.1%26.6%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$187.86M -3.5%+46.8%24.2%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$126.09M +18.1%+12.5%15.2%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$101.99M +14.6%+8.4%46.8%
Peer median (excluding ALKS) $253.66M+5.5%+11.2%25.4%

Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.17B1.11B1.66B1.56B1.48B
Cost of Revenue197.32M218.07M253.04M245.33M196.46M
Gross Profit976.43M893.73M1.41B1.31B1.28B
Gross Margin83.2%80.4%84.8%84.2%86.7%
Research & Development290.92M272.7M270.81M245.33M323.96M
Selling, General & Admin549.61M590.75M689.75M645.24M714.52M
Operating Expenses878.68M899.82M996.25M891.67M1.03B
Depreciation & Amortization78.65M77.86M74.93M28.53M27.17M
EBITDA177.6M59.77M519.48M494.86M330.89M
EBITDA Margin15.1%5.4%31.2%31.8%22.4%
Operating Income97.75M(6.09M)414.12M420.64M253.96M
Operating Margin8.3%-0.5%24.9%27.0%17.2%
Interest Income2.41M7.63M30.85M42.45M45.3M
Interest Expense11.22M13.04M23.03M22.58M12.28M
Other Income / Expenses(10.02M)(25.04M)7.4M23.11M37.49M
Income Before Tax87.73M(31.13M)421.52M443.75M291.45M
Pre-Tax Margin7.5%-2.8%25.3%28.5%19.7%
Income Tax Expense11.33M2.02M(97.64M)71.61M49.79M
Net Income(48.17M)(158.27M)355.76M367.07M241.66M
Net Margin-4.1%-14.2%21.4%23.6%16.4%
EPS (Basic)(0.30)(0.97)2.142.221.47
EPS (Diluted)(0.30)(0.97)2.102.171.43
Weighted Avg Shares160.94M163.74M166.22M165.39M164.7M
Weighted Avg Shares (Diluted)160.94M163.74M169.73M169.2M168.74M

Alkermes plc

NASDAQ:ALKS

Intrinsic Alpha fair value

Locked

Current Price

$46.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.